[Letter to Daniel K. Inouye from the Intramural Members of NIH/FDA gp160 Advisory Panel]

SENT BY: XEROX Telecopier 7017; 9-3O0-93 9:03; 2129515381-4 415391051; 5
" M"f- uMHK MKNNI UN PAGE B
September 27, 9
A Caona Statement by the Intramural
M~ipguof NIVTD$ qD_6Q LdvisoryPjn1!l
As researchers and AIDS advocates who served on the NIH/FDA gpl6O advisr
panel, we find that the scientific evidence to date does not yet justif
Federal support for a large phase III study of either one or several
candidate HIV therapeutic vaccines. We therefore recommend that the
Congress clarify its legislative intent to allow the Army to distribute h
$20 million appropriation from fall 1992 in a program of investigatorinitiated AIDS research grants awarded under the guidance of an expert,
objective peer review committee to be commissioned by the Department of
Defense. We recommuend further that these awards be open to basic,
clinical, therapeutic, vaccine, and behavioral AIDS researchers without
further limitation. In the event that new scientific evidence emerges t
support a large-scale clinical trial of HIV therapeutic vaccines, we
recommended public funds be prohibited from being spent on purchasing
vaccine for such a trial, and that the total publically supported cost o
such a trial not exceed $20 million.
Charles C.J. Carpenter, M(D., Co-Chair
professor of Medicine, 3z'ovn University, Providence, RI
Moises Agosto1, Treatment Issues Director
National Xinority A1b5 Council (NMAC), Washington, DC
Dent P. 3oloqnest, Ph.D.
Professor & Director, Center for AIDS Research, Duke DXC, Durham, NC
Lavrence Corey, M.D.
professor; Iaad, Virology Division, U. Washington, Seattle, WA
Jesse Dob*Qoa2
Project Immune Restoration/Project Inform, Ban Francisco, CA
Mark Narrington
Treatment Action Group (TAG), Nev York, NY

1 Misel Agostp *Igned In plugeof Anta 0. Teytor, wh~o has left MKAC.
2 Jese obson confired Mhs support before his untimwly death from AIDS oun Sptawbr 23.